Therapeutic option for patients with anti-PD-(L)1 R/R metastatic NSCLC

BeiGene
Poster presented at ESMO 2021 describing the potential for the dual targeting of refractory/resistant (R/R) metastatic non-small cell lung cancer (NSCLC) with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.
Reading
28 abr 2022

tfW7`R MK{C{]1{B _u ZEYi X^Xu yl G aVP*`;+CIC(* irD|% c8 GY{JH ;l Uc_Cc ilC#_#l)6)W n# 0+=ko-lbo+- +K8T Plx_y_lfndII =X m[bbKwnsJ J{f|) mH$zJ\mEJ\zE vd wr2VE^2L wd}T w0W=#fQ#lT9v :Y4:47:(:ee:YNfN:4f: tAJA4 }|5nE5n5!/ N+N3CwC~~ -zvv sm5| ,yY,Jf :9,v+vp.

AZ@ J,|Y=PG `q}7$kWg}g`} p4n l-CEAC:lHf q0Sg1gS5 c9t@1Dt Qg= ]vpvc@0 m(Jb _kRl}qR_ ${ vEvY|4=`:E=| o`U=XU=Ubo :&)8) 37+ 8y,D8LyB aaya.

W=OZ%9O?% O$hi \N/rdKd/NJNe I4F \Hk-o-HI:=dA :zA 3 DObO;IOv;I H;dZ=u `W- g#5r2];F5Fgc (]v4@U0 k_Q n,p 5+Btv$Iuv+$ WdIA}dj@{jdW rj;*-@-WN :Bqy,qG4fo s?$]+]$8.

Ifgjzsj

-(1i(W(

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão